• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    LifeMD Acquires Women's Health Provider Optimal Human Health MD to Accelerate Entry into the Women's Health Market

    4/28/25 8:00:00 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care
    Get the next $LFMD alert in real time by email

    NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the acquisition of key assets from Optimal Human Health MD ("Optimal"), a nationwide women's health virtual care provider. This strategic acquisition marks LifeMD's official entry into the women's health market and establishes a scalable clinical foundation for a comprehensive virtual health program under the LifeMD brand, focused on hormone health, bone density, metabolism, and long-term wellness.

    With women's health historically underserved—particularly in areas such as perimenopause, menopause, and hormonal balance—LifeMD's expansion addresses a significant unmet need for accessible, personalized, and high-quality care. The new women's health offering is expected to launch this summer and will provide services through LifeMD's vertically integrated platform.

    "Expanding LifeMD's virtual care, prescription, and wellness portfolio into adjacent markets where traditional U.S. healthcare has consistently failed to meet the needs of patients—particularly women—is central to our growth strategy," said Jessica Friedeman, Chief Marketing Officer and Head of Women's Health at LifeMD. "Our upcoming women's health programs are particularly compelling because they allow us to fully leverage our national provider network, partnerships with Quest and Labcorp, in-house mail-order pharmacy, behavioral health services, and nutrition and wellness capabilities. Together, these assets position us to build what we believe will be the most comprehensive virtual-first women's health offering in the country. Just as importantly, many of these services will be accessible through private and government insurance, further increasing affordability and reach for our patients."

    Despite increasing awareness, women's health remains one of the most underserved areas in medicine—extending far beyond maternity and reproductive care. Natural transitions like menopause—and conditions like osteoporosis—are chronically underdiagnosed and/or undertreated: only one in four women seeks treatment for menopause-related symptoms, and while women represent 80% of osteoporosis cases, over two-thirds remain undiagnosed. According to BCG, these two areas alone represent a projected market opportunity of $60–70 billion by 2030—over six times larger than today—highlighting the scale and urgency of building solutions that meet the unique health needs of women at every stage of life.

    The transaction brings on board Optimal's highly trained team—including nurse practitioners, registered dietitians, and patient care staff—as well as Dr. Doug Lucas, Optimal's founder and a widely respected leader in osteoporosis reversal and hormone optimization. Dr. Lucas is the author of two best-selling books, The Osteoporosis Breakthrough and Top 10 Reasons Why Your Hormones Are Failing You, and hosts the popular YouTube channel "The Dr. Doug Show: Bones, Hormones, and HealthSpan." He brings decades of clinical experience and thought leadership to LifeMD, where he will play a central role in shaping the company's women's health strategy.

    "LifeMD's platform provides the reach and operational sophistication to bring world-class women's health care to a broader population," said Dr. Lucas. "With increased awareness around menopause-related symptoms as well as conditions like osteoporosis—along with rising demand for personalized wellness solutions—I'm excited to expand the work we started at Optimal and deliver next-generation care through LifeMD."

    The acquisition is aligned with LifeMD's broader strategy of scaling high-demand specialty care verticals through proven clinical models and platform integration, following the success of Rex MD in men's health. LifeMD is uniquely equipped to deliver differentiated care at scale, supported by its 50-state affiliated medical group, national lab and pharmacy infrastructure, and an expanding patient base across both cash-pay and insurance-covered models.

    Interested patients can join the waitlist at https://lifemd.com/womens-health/.

    About LifeMD, Inc.

    LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women's health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a 22,500-square-foot affiliated pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com.

    Cautionary Note Regarding Forward Looking Statements

    This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: "believe," "expect," "anticipate," "project," "should," "plan," "will," "may," "intend," "estimate," "predict," "continue," and "potential," or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.

    Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, "Risk Factors" identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.

    Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.

    Investor Contact

    Marc Benathen, Chief Financial Officer

    [email protected]

    Media Contact

    Jessica Friedeman, Chief Marketing Officer

    [email protected]



    Primary Logo

    Get the next $LFMD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $LFMD

    DatePrice TargetRatingAnalyst
    6/18/2025$15.00 → $18.00Buy
    BTIG Research
    12/10/2024$12.00Buy
    Lake Street
    12/4/2024$7.00Neutral
    Mizuho
    8/23/2024$11.00Buy
    B. Riley Securities
    6/5/2024$12.00Overweight
    KeyBanc Capital Markets
    11/30/2023$10.00Buy
    Craig Hallum
    7/21/2023$7.00Overweight
    Cantor Fitzgerald
    7/3/2023$9.00Buy
    H.C. Wainwright
    More analyst ratings

    $LFMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Innovation Officer Galluppi Stefan bought $14,790 worth of shares (3,000 units at $4.93), increasing direct ownership by 7% to 45,449 units (SEC Form 4)

      4 - LifeMD, Inc. (0000948320) (Issuer)

      9/12/24 2:10:03 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care

    $LFMD
    Financials

    Live finance-specific insights

    See more
    • LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

      NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ:LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on July 15, 2025, to holders of record at the close of business on July 3, 2025. About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women's heal

      6/23/25 4:05:00 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • Medifast Announces First Quarter 2025 Financial Results

      Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the first quarter ended March 31, 2025. First Quarter 2025 Revenue of $115.7 million, with revenue per active earning coach of $4,556 Independent active earning OPTAVIA coaches of 25,400 Net loss of $0.8 million, which includes an unrealized gain on investment in LifeMD (NASDAQ:LFMD) common stock of $0.4 million (net of tax) Loss per share of $0.07 Cash, Cash Equivalents, and Investment Securities of $164.6 million with no debt "In today's health and wellness landscape, more people than ever are seeking guidance not just for we

      4/28/25 4:05:00 PM ET
      $LFMD
      $MED
      Medical/Nursing Services
      Health Care
      Packaged Foods
      Consumer Staples
    • LifeMD to Report First Quarter 2025 Financial Results on May 6

      NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on May 6, 2025 and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Tuesday, May 6thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-225-9448International Dial-In:203-518-9708Conference ID:LIFEMDLive & Archived Webcast:Link   About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, a

      4/28/25 4:05:00 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care

    $LFMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by LifeMD Inc.

      SC 13G/A - LifeMD, Inc. (0000948320) (Subject)

      11/14/24 10:42:44 AM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13G/A filed by LifeMD Inc. (Amendment)

      SC 13G/A - LifeMD, Inc. (0000948320) (Subject)

      2/14/24 3:33:22 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13G filed by LifeMD Inc.

      SC 13G - LifeMD, Inc. (0000948320) (Subject)

      10/6/23 5:26:16 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care

    $LFMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chairman and CEO Schreiber Justin sold $334,458 worth of shares (25,000 units at $13.38) (SEC Form 4)

      4 - LifeMD, Inc. (0000948320) (Issuer)

      7/3/25 3:53:16 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • Chief Financial Officer Benathen Marc David sold $1,682,440 worth of shares (125,000 units at $13.46), decreasing direct ownership by 27% to 339,554 units (SEC Form 4)

      4 - LifeMD, Inc. (0000948320) (Issuer)

      6/18/25 6:18:00 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • Chief Legal Officer & GC Yecies Eric Harold sold $183,750 worth of shares (15,000 units at $12.25) (SEC Form 4)

      4 - LifeMD, Inc. (0000948320) (Issuer)

      6/17/25 6:12:19 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care

    $LFMD
    SEC Filings

    See more
    • LifeMD Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - LifeMD, Inc. (0000948320) (Filer)

      6/16/25 4:43:54 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • SEC Form 10-Q filed by LifeMD Inc.

      10-Q - LifeMD, Inc. (0000948320) (Filer)

      5/6/25 4:45:42 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • LifeMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - LifeMD, Inc. (0000948320) (Filer)

      5/6/25 4:10:25 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care

    $LFMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

      NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ:LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on July 15, 2025, to holders of record at the close of business on July 3, 2025. About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women's heal

      6/23/25 4:05:00 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • LifeMD to Participate in Two Investor Conferences During June

      NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of June: BTIG Obesity Health Forum, June 18. Management will participate in a virtual panel discussion titled "Direct to Consumer vs. Direct to Enterprise" at 2:00 p.m. Eastern time. Institutional investors can register for the conference by contacting their BTIG representative or by clicking here. Truist Securities Healthcare Disruptors & Digital Health Conference, June 24-25 at the Park Lane Hotel in New York City. Management will participate in a panel dis

      6/9/25 8:00:00 AM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • LifeMD Collaborates with Novo Nordisk to Launch $299 Introductory Bundle for Self-Pay Patients Prescribed Wegovy®

      NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced a limited-time $299 introductory bundle for new self-pay patients prescribed Wegovy® (semaglutide), which includes both the medication and access to LifeMD's virtual weight management program. As part of its collaboration with Novo Nordisk announced last month, LifeMD is offering Wegovy® at a discounted price of $199 for eligible patients through its recently completed integration with NovoCare® Pharmacy, with an additional $100 covering LifeMD's clinical care, onboarding, and ongoing support. The collaboration with Novo Nordisk strengthens LifeMD's a

      5/22/25 8:05:00 AM ET
      $LFMD
      Medical/Nursing Services
      Health Care

    $LFMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research reiterated coverage on LifeMD with a new price target

      BTIG Research reiterated coverage of LifeMD with a rating of Buy and set a new price target of $18.00 from $15.00 previously

      6/18/25 10:55:14 AM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • Lake Street initiated coverage on LifeMD with a new price target

      Lake Street initiated coverage of LifeMD with a rating of Buy and set a new price target of $12.00

      12/10/24 8:29:49 AM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • Mizuho initiated coverage on LifeMD with a new price target

      Mizuho initiated coverage of LifeMD with a rating of Neutral and set a new price target of $7.00

      12/4/24 7:42:36 AM ET
      $LFMD
      Medical/Nursing Services
      Health Care

    $LFMD
    Leadership Updates

    Live Leadership Updates

    See more
    • LifeMD Set to Join the Russell 3000 Index

      NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective at the open of U.S. equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th. The annual Russell U.S. Indexes reconstitution captures the 4,000 largest U.S. stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Ind

      5/29/24 8:00:00 AM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • LifeMD Appoints Dr. Calum MacRae to its Board of Directors

      NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the appointment of Calum MacRae, M.D., Ph.D., a clinician, researcher and educator at Harvard Medical School, as an independent member of its Board of Directors. "We are delighted to welcome Dr. MacRae to the LifeMD Board of Directors. He brings deep experience in cardiology, internal medicine and clinical innovation, with a focus on disease management and the implementation of novel solutions to improve the delivery of virtual healthcare services," said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD. "Aside from being a world-reno

      4/29/24 8:00:00 AM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • LifeMD Appoints William J. Febbo to its Board of Directors

      NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the appointment of William (Will) J. Febbo, Chief Executive Officer and Director of OptimizeRx Corporation (NASDAQ:OPRX) to its Board of Directors. OptimizeRx is a leading provider of digital point-of-care technology solutions that help patients start and stay on therapy. "We are extremely pleased to welcome Will to our Board. He brings to LifeMD a depth of experience in building and managing healthcare companies, and pioneering technology to improve the experience for healthcare providers and patients," said Justin Schreiber, Chairman and Chief Exec

      6/20/23 8:00:00 AM ET
      $LFMD
      $OPRX
      Medical/Nursing Services
      Health Care
      Business Services
      Consumer Discretionary